// App-Quantinova.ai

970 : Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Researchers

Presenter

  • Morten P Oksvold

Principal Investigators

  • Ulrika Warpman Berglund

  • Helge Gad

  • Baoyan Bai

  • Trond Stokke

  • Idun D Rein

  • Therese Pham

  • Kumar Sanjiv

  • Geir Frode y

  • Jens Henrik Norum

  • Erlend B. Smeland

  • June Helen Myklebust

  • Thomas Helleday

  • Thea Kristin Vtsveen

Medical Centers

  • KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

  • Oslo University Hospital, Institute for Cancer Research, Oslo, Norway

  • Scilifelab, Karolinska Institute, Stockholm, Sweden

  • Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom

  • Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0376, Norway

  • KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

  • Department of Radiation Biology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway

  • Department of Radiation Biology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway

  • Department of Radiation Biology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway

  • Dept for Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

  • KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

  • Weston Park Cancer Centre, University of Sheffield, Sheffield, Tuvalu

  • Department of Radiation Biology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway

  • KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

Locations

  • Norway

  • Sweden

  • United Kingdom

  • Tuvalu

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Follicular lymphoma

  • Burkitt lymphoma

  • B cell lymphomas

  • Solid malignancies

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved